Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Calverley

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
BMC Pulmonary Medicine|August 22, 2015
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseChristine R Jenkins, Dirkje S Postma, Antonio R Anzueto, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2015
A score to predict short-term risk of COPD exacerbations (SCOPEX)Barry J Make, Göran Eriksson, Peter M Calverley, et al.
American Journal of Respiratory and Critical Care Medicine|January 28, 2006
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trialElizabeth A Laude, Nicholas C Duffy, Chloe Baveystock, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 30, 2016
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPDPeter M Calverley, Göran Eriksson, Christine R Jenkins, et al.
Respiratory Medicine|August 20, 2013
Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristicsDirkje S Postma, Antonio R Anzueto, Christine Jenkins, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 30, 2017
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trialsGöran Eriksson, Peter M Calverley, Christine R Jenkins, et al.
The European Respiratory Journal|May 30, 2015
Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and DAntonio Anzueto, Christine R Jenkins, Barry J Make, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2012
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspneaMark B Parshall, Richard M Schwartzstein, Lewis Adams, et al.
Chest|March 16, 2007
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placeboJoan B Soriano, Don D Sin, Xuekui Zhang, et al.
Perioperative Medicine (London, England)|December 3, 2025
Correction: The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial)Lisa Loughney, Malcolm A West, Helen Moyses, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
BMC Pulmonary Medicine|August 22, 2015
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseChristine R Jenkins, Dirkje S Postma, Antonio R Anzueto, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2015
A score to predict short-term risk of COPD exacerbations (SCOPEX)Barry J Make, Göran Eriksson, Peter M Calverley, et al.
American Journal of Respiratory and Critical Care Medicine|January 28, 2006
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trialElizabeth A Laude, Nicholas C Duffy, Chloe Baveystock, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 30, 2016
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPDPeter M Calverley, Göran Eriksson, Christine R Jenkins, et al.
Respiratory Medicine|August 20, 2013
Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristicsDirkje S Postma, Antonio R Anzueto, Christine Jenkins, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 30, 2017
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trialsGöran Eriksson, Peter M Calverley, Christine R Jenkins, et al.
The European Respiratory Journal|May 30, 2015
Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and DAntonio Anzueto, Christine R Jenkins, Barry J Make, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2012
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspneaMark B Parshall, Richard M Schwartzstein, Lewis Adams, et al.
Chest|March 16, 2007
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placeboJoan B Soriano, Don D Sin, Xuekui Zhang, et al.
Perioperative Medicine (London, England)|December 3, 2025
Correction: The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial)Lisa Loughney, Malcolm A West, Helen Moyses, et al.
Pageof 3